Interview: Bart Roep – Director, Diabetes Expert Center, Leiden…
Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than…
Address: Albinusdreef 2, 2333 ZA Leiden, the Netherlands
,Netherlands
Tel: +31 71 5269111
Web: https://www.lumc.nl/home/
One of the eight medical centres in the Netherlands, the Leiden University Medical Center (LUMC) has five core tasks:
patient care
scientific research
education
study programmes
continuing education.
The LUMC employs 7000 people.
Patient care is largely focused on highly specialised care, the sort of care that cannot be provided anywhere else. The LUMC also offers a broad package of top-level clinical care, including organ transplants, cardiovascular interventions and all types of bone marrow transplants.
The research conducted in the LUMC is both fundamental and patient- and care-oriented. A considerable portion of the research centres on the translation from fundamental research to its use in patient care (from bench to bedside and vice versa). A good example is the recently opened C.J. Gorter Center, one of the world’s prominent centres in the area of MRI research.
The C.J. Gorter Center has installed the first 7Tesla MRI scanner in the Netherlands for use with humans. The research in the LUMC will be aimed at early diagnosis of Alzheimer’s, a better understanding of migraine, the energy economy in healthy people and patients with diabetes, and the process of ageing. Important research themes in the LUMC are: ageing, neurosciences, vascular medicine, infectious diseases and immunology, cancer immunotherapy, regenerative medicine, oncogenetics, genetic epidemiology and bio-informatics.
The LUMC offers degree courses in Medicine and Biomedical Sciences. The training of medical specialists is also a core task of the LUMC. Medical specialists are trained in 27 specialities in collaborative clusters of general hospitals in the vicinity.
The Boerhaave Committee is another part of the LUMC. Its focus is the provision of high-quality training at post-academic and post-graduate as well post-vocational levels.
patient care
scientific research
education
study programmes
continuing education
Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
Having one of the highest penetration rates in Europe, generic medicines play a very important role in the Dutch pharmaceutical market. As this is the principal association for the generics…
While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate.…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
See our Cookie Privacy Policy Here
